Alerts will be sent to your verified email
Verify EmailGLAXO
Glaxosmithkline Phar
|
Alkem Laboratories
|
Aurobindo Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
8.9 % | 12.1 % | n/a |
R&D as a % of Total Sales
|
0.07 % | 5.0 % | 5.05 % |
Financials
|
|||
5 yr Average ROE
|
40.73 % | 17.42 % | 13.97 % |
5yr average Equity Multiplier
|
1.9 | 1.42 | 1.51 |
5yr Average Asset Turnover Ratio
|
0.94 | 0.89 | 0.71 |
5yr Avg Net Profit Margin
|
24.91 % | 13.9 % | 12.77 % |
Price to Book
|
28.24 | 4.8 | 1.97 |
P/E
|
59.4 | 26.57 | 18.49 |
5yr Avg Cash Conversion Cycle
|
-107.65 Days | -31.98 Days | -49.62 Days |
Inventory Days
|
52.59 Days | 55.32 Days | 59.48 Days |
Days Receivable
|
22.78 Days | 41.28 Days | 28.34 Days |
Days Payable
|
144.46 Days | 114.28 Days | 115.71 Days |
5yr Average Interest Coverage Ratio
|
479.64 | 24.2 | 43.78 |
5yr Avg ROCE
|
44.44 % | 22.93 % | 16.69 % |
5yr Avg Operating Profit Margin
|
25.23 % | 18.1 % | 19.28 % |
5 yr average Debt to Equity
|
0.0 | 0.21 | 0.21 |
5yr CAGR Net Profit
|
20.96 % | 9.76 % | 2.21 % |
5yr Average Return on Assets
|
21.84 % | 12.26 % | 9.18 % |
Shareholdings
|
|||
Promoter Holding
|
75.0 % | 55.13 % | 51.82 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 16.92 % |
Change in Promoter Holding (3 Yrs)
|
0.0 | -2.0 % | -0.01 % |
Change in Mutual Fund Holding (3 Yrs)
|
1.0 % | 7.45 % | 8.12 % |
Glaxosmithkline Phar
|
Alkem Laboratories
|
Aurobindo Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|